A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A (Abstract) (LDN, low dose naltrexone)

Orphanet J Rare Dis
16 October 2021
https://pubmed.ncbi.nlm.nih.gov/34656144/

Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases

Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A)

PLoS One
16 January 2019
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334894/

Low Dose Naltrexone in Dermatology

J Drugs Dermatol
March 2019
https://jddonline.com/articles/dermatology/S1545961619P0235X

Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats

J Neurosci Res
October 2020
https://pubmed.ncbi.nlm.nih.gov/32588471/